Navigation Links
Major State Grant Accelerates Research and Development of Novel Cancer Therapy
Date:9/5/2008

BOCA RATON, Fla., Sept. 5 /PRNewswire-USNewswire/ -- The Florida Technology, Research and Scholarship Board recently awarded Florida Atlantic University researcher Dr. Herbert Weissbach, distinguished professor and director of the Center for Molecular Biology and Biotechnology in the Charles E. Schmidt College of Science, and CHS Resources LLC (CHS), $184,294 as part of the State University Research Commercialization Assistance Grant program (SURECAG). SURECAG was established by the Florida Legislature in 2007 to promote the commercialization of university research products to enhance the state's economy and its public universities. With these funds, universities are able to promote their commercialization endeavors by securing patents, establishing startup companies, developing licensing agreements and attracting private investments.

FAU, together with CHS (which licensed this technology from FAU), submitted a proposal for Weissbach's discovery of a novel combination of agents that work to preferentially target and kill cancer cells. In addition, CHS was instrumental in providing FAU with a matching grant -- a stipulation of the SURECAG program -- for a total of $368,588 for research and development. CHS is currently developing this therapy for treatment of actinic keratosis (AK), a precancerous skin condition, and "proof-of-concept" studies are ongoing. CHS is simultaneously developing an over-the-counter skin protective agent with unique antioxidant properties.

"SURECAG is designed to create a more vital link between venture capitalists, industry and Florida's state universities," said Dr. Gary Perry, dean of the Charles E. Schmidt College of Science. "This grant is essential to support product development activities necessary to help CHS obtain approval from the FDA to perform clinical trials that will lead to drug approval."

Weissbach and his team initially identified a lead compound that in combination with an oxidizing agent or age
'/>"/>

SOURCE Florida Atlantic University
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Aspirin Named 8th World Wonder by Majority of Americans
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
5. ArtJen Announces Major Clinical Trial of Its Patented Weight Loss Product FBCx
6. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
7. EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimers, Schizophrenia and Huntingtons Diseases
8. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
9. Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting
10. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
11. Fabre Kramer Pharmaceuticals Receives Decision From FDA on Gepirone ER for Major Depressive Disorder

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...Nov. 6 Derma Sciences,...advanced wound care products, announced plans to r...t on Monday, November 16, 2009. The Company will h... results at 11:00 am EST. Interested parties shoul... (international), with passcode 81416481 to access...
(Date:11/6/2009)... Nov. 6 Philips Respironics applau...and Prevention (CDC) to raise awareness about an i...fficiency. The CDC,s release of the first-ever gov...s in sleeplessness is a milestone in quantifying t...-time educator, industry leader and sleep therapy ...
(Date:11/6/2009)...PRNewswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq:...ort financial results for the second quarter ended...30, 2010 on Wednesday, November 18, 2009 at 5:00 P... to discuss those results on Thursday, November 19...cond Quarter Results Conference Call Instructions ...
Breaking Medicine Technology:Derma Sciences Announces Date of Its Third Quarter 2009 Earnings Release and Conference Call 2Statement by Don Spence, CEO, Philips Home Healthcare Solutions, Endorsing CDC Educational Initiatives to Raise Awareness of Sleep Deprivation 2Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 Second Quarter Financial Results 2Ulcerative colitis treatment reduces need for surgery by almost half 58614 1Ulcerative colitis treatment reduces need for surgery by almost half 58614 2Platelet rich plasma 3A Does it work 3F 58610 1Platelet rich plasma 3A Does it work 3F 58610 2Platelet rich plasma 3A Does it work 3F 58610 3Entomological Society of America names 2009 award winners 10202 1Entomological Society of America names 2009 award winners 10202 2
...16 DURECT Corporation (Nasdaq: DRRX ) announced...b clinical trial conducted by Endo Pharmaceuticals...ay patch under development for the treatment of ch...candidate was reviewed with the U.S. Food and Drug...hase II meeting with the FDA on February 19, 2009....
...nnocoll, Inc., a privately-held biopharmaceutical ...dosed in the first of two ongoing U.S. phase 3 cli...ary, Innocoll Technologies Ltd, to investigate Col...tion of surgical site infections. , , The trial i...es across the U.S. and has enrolled 1,500 diabetic...
Other Medicine Technology:DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program 2DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program 3DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program 4DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program 5Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients 2Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients 3
(Date:11/8/2009)... 3D Global Solutions is p...program managing the proposal effort for ReSound w...VA Digital Hearing Aid contract. The award include...he Department of Defense and other federal agencie... November 8, 2009 -- 3D Global Solutions is please...
(Date:11/8/2009)... Men’s Health Netwo...eir health risks, especially those linked to expos...from military service. Bladder cancer is one of th...terans, especially those who once smoked or curren...ashington DC (PRWEB) November 8, 2009 -- Men&rsquo...
(Date:11/8/2009)...,, WASHINGTON, Nov. 7 /PRNewswire-USNewswire/ -...tupak, Pitts, Kaptur, Dahlkemper, Smith, Ellsworth...Care for America Act" (H.R. 3962). The amendment m...funding for abortion and for benefits packages tha... both those who receive affordability credits and ...
(Date:11/8/2009)...,, Nation,s largest network of Hispanic health...h care reform in 2009 ,, WASHINGTON, Nov. 7 /P...f Representatives showed they have heard the voice...ealth Care for America Act. Now the Senate must de... health care reform," said Dr. Jane L. Delgado, Pr...
(Date:11/8/2009)...,, WASHINGTON, Nov. 8 /PRNewswire-USNewswire/ -...rica (PhRMA) Senior Vice President Ken Johnson rel...health care reform bill: ,, "We are disappointe...ess echoed by millions of hardworking Americans as...use of Representatives who voted against the bill....
Breaking Medicine News(10 mins):Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 2Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 3Health News:Veterans' Day Reminder from Men's Health Network: Pay Attention to Bladder Cancer Symptoms and Risk Factors 2Health News:Veterans' Day Reminder from Men's Health Network: Pay Attention to Bladder Cancer Symptoms and Risk Factors 3Health News:Family Research Council Praises Passage of Pro-life Amendment to Health Care Bill 2Health News:National Alliance for Hispanic Health President and CEO Applauds House Action, Calls on Senate to Pass Health Reform in 2009 2Health News:PhRMA Statement on House Passage of Health Care Reform Bill 2Health News:PhRMA Statement on House Passage of Health Care Reform Bill 3
...earchers at the Mayo clinic in a new study observe...tion from a hot tub bath. No doubt it is relaxing ...th club. The experts advice you to be sure of keep...igated two patients presenting with 'hot tub lung'...
...loyment of an airbag after an automobile accident ...eye problems. It's now well validated that airbags...es. //However, the effect of airbags on the eye ha...oked at the severity of the various eye injuries t...
...ies with the worst pollution in the US have more h...re's increasing proof for a tie between environmen...e University of California report upon the effect/...an areas. They found that there was little differe...
...iet rich in alpha-linoleic acid reduced cardiac ev...se (CAD) is a major public health problem in South.... The high prevalence of CAD is not fully explaine... of a Mediterranean type diet on cardiac risk in a...
...ording to a new study it is observed that thalido...diagnosed multiple myeloma patients when combined ...om the Mayo Clinic in Rochester, Minn.// gave 60 n...the combination. Researchers also observed an impr...
...en who engage in substantial leisure time activity...hip fracture. A new report from the long-running N...pausal women in the US,// shows that keeping activ...e in hip fracture risk. Three hours MET is similar...
Other Medicine News:
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
Medicine Products: